The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy

The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy

Inhibitors of the DNA damage signaling kinase ATR increase tumor cell killing by chemotherapies that target DNA replication forks but also kill rapidly proliferating immune cells including activated T cells. Nevertheless, ATR inhibitor (ATRi) and radiotherapy (RT) can be combined to generate CD8+ T...

Full description

Bibliographic Details
Main Authors: Frank P. Vendetti, Pinakin Pandya, David A. Clump, Sandra Schamus-Haynes, Meysam Tavakoli, Maria diMayorca, Naveed M. Islam, Jina Chang, Greg M. Delgoffe, Jan H. Beumer, Christopher J. Bakkenist
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-02-01
Series:JCI Insight
Subjects:
Immunology
Oncology
Online Access:https://doi.org/10.1172/jci.insight.165615

Internet

https://doi.org/10.1172/jci.insight.165615

Similar Items